Today: 25 January 2026
Subscribe
Browse Category

NYSE:ABBV News 9 January 2026 - 14 January 2026

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

New York, Jan 14, 2026, 11:23 EST — Regular session Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%. Healthcare outperformed the broader market. The Health Care Select Sector SPDR ETF edged up slightly, with Merck, Pfizer, and AbbVie each adding about 0.6%, 0.6%, and 0.5%, respectively.…
14 January 2026
········
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

New York, January 13, 2026, 14:45 ET — Regular session AbbVie shares slipped 0.1% to $219.83 Tuesday afternoon after the drugmaker announced a three-year deal with the Trump administration. The pact aims to lower certain drug prices in return for exemptions from tariffs and future pricing rules. The deal arrives amid investor attempts to figure out how “lower prices” might…
13 January 2026
·····
AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

New York, Jan 12, 2026, 19:48 EST — After-hours AbbVie shares barely moved in after-hours Monday following a new three-year pricing pact with the Trump administration. The drugmaker also announced two deals to strengthen its pipeline and boost U.S. manufacturing. The stock slipped less than 0.1% to $220.04. The timing is crucial as Washington ramps up pressure on drugmakers over…
13 January 2026
·····
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

New York, January 12, 2026, 13:31 EST — Regular session AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81. (Reuters) Investors are focused on how…
12 January 2026
·····
AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

New York, January 11, 2026, 11:10 EST — Market closed AbbVie Inc. (ABBV.N) closed Friday down 1.8% at $220.08. As U.S. markets remain closed over the weekend, chatter about a potential deal lingers heading into Monday. The J.P. Morgan Healthcare Conference week draws attention now, serving as a hotspot for new guidance, pipeline updates, and those crucial side-room talks that…
11 January 2026
····
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

NEW YORK, Jan 10, 2026, 13:31 EST — Market closed U.S. healthcare stocks ended the week weaker, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.5% to $157.31 on Friday. This ETF, often seen as a benchmark for major U.S. healthcare companies, has shown volatility as investors brace for a packed schedule of sector developments. The industry’s annual…
10 January 2026
······
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

NEW YORK, January 10, 2026, 11:17 AM EST — The market has closed. Shares of AbbVie Inc slipped 1.8% to close Friday at $220.08, wrapping up a choppy session marked by shifting guidance and takeover rumors. AbbVie disclosed in a regulatory filing that it anticipates around $1.3 billion in acquired in-process research and development (IPR&D) and milestone expenses in Q4—costs…
10 January 2026
·····
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

New York, January 9, 2026, 20:18 (EST) — Market closed AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was in talks to acquire cancer-drug developer Revolution Medicines. Since 2023, AbbVie has spent over $20 billion on acquisitions, aiming to…
10 January 2026
······
AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

NEW YORK, Jan 9, 2026, 12:28 PM EST — Regular session AbbVie Inc (ABBV) shares fell about 0.8% in midday New York trade on Friday after the drugmaker trimmed its 2025 profit outlook and brushed off a report tying it to a takeover of cancer biotech Revolution Medicines. The stock was down $1.78 at $222.35. AbbVie said in an emailed…
9 January 2026
·····
1 2

Stock Market Today

  • Schaffer Corporation (ASX:SFC) Insiders Bolster Holdings to 46%, Signal Growth Confidence
    January 24, 2026, 6:42 PM EST. Insiders of Schaffer Corporation Limited (ASX:SFC) hold a substantial 46% stake, indicating strong vested interest in the company's future. The top five shareholders control about 51% of shares, consolidating significant influence. Recently, insiders have increased their share purchases, potentially signaling confidence in stock price appreciation. Institutional investors hold a notable but smaller stake, affirming some professional backing. CEO John Schaffer is the largest individual shareholder with 16% ownership, alongside key stakeholders Mutual Trust Pty Ltd and Blanka Schaffer, each holding 9.6%. Hedge funds show minimal involvement, and there is currently no analyst coverage, suggesting the stock remains under the radar. The insider activity and ownership concentration may impact Schaffer's upcoming market trajectory.
Go toTop